Actively Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Led by Exelixis · Updated on 2026-02-17
150
Participants Needed
9
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
CONDITIONS
Official Title
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Minimum life expectancy of 65 12 weeks
- Recurrent locally advanced or metastatic solid tumors
- Adequate end organ and bone marrow function
You will not qualify if you...
- Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease
- History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia
- Acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea
- Known history of immunodeficiency virus (HIV) unless specific criteria are met
- Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody
- Major surgery within 4 weeks before the first dose of study treatment
- Received radiation therapy within 2 weeks before the first dose of study treatment
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Exelixis Clinical Site #5
Rogers, Arkansas, United States, 72758
Actively Recruiting
2
Exelixis Clinical Site #9
Los Angeles, California, United States, 90033
Actively Recruiting
3
Exelixis Clinical Site #6
Washington D.C., District of Columbia, United States, 20057
Actively Recruiting
4
Exelixis Clinical Site #4
Orlando, Florida, United States, 32827
Actively Recruiting
5
Exelixis Clinical Site #3
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
6
Exelixis Clinical Site #7
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
7
Exelixis Clinical Site #2
Huntersville, North Carolina, United States, 28078
Actively Recruiting
8
Exelixis Clinical Site #8
Houston, Texas, United States, 77030
Actively Recruiting
9
Exelixis Clinical Site #1
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
E
Exelixis Clinical Trials
CONTACT
B
Backup or International
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here